Skip to main
RAPP

RAPP Stock Forecast & Price Target

RAPP Analyst Ratings

Based on 6 analyst ratings
Buy
Strong Buy 50%
Buy 50%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Rapport Therapeutics is currently in a strong position with their lead asset RAP-219, an AMPA modulator, expected to enter Phase 3 trials in 2026 for the treatment of focal onset epilepsy and bipolar mania. Their Phase 2 results have been pulled forward to 4Q26, and they have modified their statistical analysis plan to increase sample size and provide 80% power to detect a 4-point difference on the Young Mania Rating Scale. Based on their strong clinical execution and increased confidence in RAP-219's mechanism, analysts project peak sales of $3.3B for RAP-219. However, there is still some risk involved, as competition in the epilepsy and bipolar mania markets is stiff, and delays in clinical trials due to third-party suppliers could potentially affect results.

Bears say

Rapport Therapeutics is a clinical-stage biotechnology company with a portfolio of programs focused on neurological and psychiatric disorders. While the company's pipeline appears promising, there are a few key concerns that lead to a negative outlook on its stock. Firstly, the company's lead candidate, RAP-219, is being developed for indications that are already well-served by currently available treatments. Additionally, there are concerns about potential long-term cognitive and behavioral side effects of targeting the AMPA receptor, as well as the potential for delays or errors in clinical trials. Overall, while the company's unique approach and potential for positive clinical outcomes are notable, these risks make it a risky investment at this time.

RAPP has been analyzed by 6 analysts, with a consensus rating of Buy. 50% of analysts recommend a Strong Buy, 50% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Rapport Therapeutics Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Rapport Therapeutics Inc (RAPP) Forecast

Analysts have given RAPP a Buy based on their latest research and market trends.

According to 6 analysts, RAPP has a Buy consensus rating as of Aug 24, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $60.83, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $60.83, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Rapport Therapeutics Inc (RAPP)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.